Anti-inflammatory effects of alcohol and polyphenolic content of beer

ISRCTN	ISRCTN95345245
DOI	https://doi.org/10.1186/ISRCTN95345245
Protocol serial number	Beer-01-2010
Sponsor	Cerveceros de España (Spain)
Funder	Cerveceros de España (Spain)

Submission date: 07/09/2010
Registration date: 04/10/2010
Last edited: 04/09/2014

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Circulatory System

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Ramon Estruch
Scientific

Department of Internal Medicine
Hospital Clinic de Barcelona
c/Villarroel nº170
Barcelona
08036
Spain

Phone	+34 93 227 93 65
Email	restruch@clinic.ub.es

Study information

Primary study design	Interventional
Study design	Open randomised crossover controlled clinical trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title	Scientific basis of beneficial effects of moderate beer consumption in the cardiovascular system: anti-inflammatory effects of alcohol and polyphenolic content of beer
Study objectives	The benefit of the main components of beer, namely ethanol and polyphenolic content is synergistic. No adverse events will be observed.
Ethics approval(s)	Institutional Review Board of the Hospital Clinic of Barcelona, 20/07/2010
Health condition(s) or problem(s) studied	Arteriosclerosis
Intervention	Intervention 1: 92 ml/day of gin (28 g ethanol/day) Intervention 2: 660 ml/day of lager beer (28 g ethanol/day) Intervention 3: 990 ml/day of dealcoholised lager beer (equivalent amount of polyphenols to 660 ml of beer) Initial wash-out period (15 days) First intervention - 28 days Second intervention - 28 days Third intervention - 28 days
Intervention type	Drug
Phase	Not Applicable
Drug / device / biological / vaccine name(s)	Beer
Primary outcome measure(s)	1. Endothelial function with a color Doppler Toshiba PowerVision ultrasound apparatus using multifrequency transducers (B-mode, 7.5 to 10 MHz; Doppler, 3.75 MHz). 2. Leukocyte adhesion molecule expression: lymphocyte and monocyte adhesion molecules on these cells will be marked with monoclonal antibodies (MAb) conjugated with fluorescein-isothiocyanate (FITC) and phycoerythrin (PE) by direct double immunofluorescence. The MAb of the adhesion molecules used will be: anti-CD11a (LFA-1), anti-CD40L, anti-CD11b (Mac-1) (Bender MedSystems Diagnostics, Vienna), anti-Syalil Lewis (anti-CD15s) (Pharmingen, San Diego, CA), anti-CD49d (VLA-4) (Cytogmos). The monoclonal antibodies used to mark the T-lymphocytes will be anti-CD2 and monocytes, anti-CD14 (Caltag Laboratories, Burlingame, CA). 3. Soluble adhesion molecules: the following serum soluble adhesion molecules will be determined by enzyme-linked immunosorbent assay (ELISA) kits: soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule 1 (sVCAM-1), sE-selectin, and sP-selectin, as well as soluble monocyte chemotactic protein-1 (sMCP-1), tumour necrotising factor-alpha (TNF-a), and interleukin B (IL-1B) (Immunotech) 4. Nuclear Factor Kappa B by western blot of peripheral blood mononuclear cells. 5. Genes and proteins involved in inflammatory response will be determined by real time polymerase chain reaction (PCR) and Western blot analysis (MCP-1, TF and TFPI, as markers of inflammation and LRP and the LDL receptor as lipoproteic receptors). Moreover, the expression metalloproteases and their activity will also be analysed. All variables (primary and secondary outcomes) will be measured at baseline and after each intervention period.
Key secondary outcome measure(s)	1. Medical record: a complete medical record will be obtained from all participants, which included data on alcohol intake, smoking and dietary habits. Blood pressure and heart rate will be measured with an electronic apparatus Omron HEM-705CP (Netherlands). 2. Nutrition assessment and general analyses: all participants will complete a validated nutritional questionnaire at baseline to determine the total quantity of calories ingested in the previous month as well as the proportion corresponding to carbohydrates, lipids and proteins. Overall nutrition will be determined by percentage of ideal weight, lean body mass and body mass index. Waist perimeter will be measured. The proteic nutrition will be determined on the basis of the following parameters: haemoglobin, total lymphocyte count, total proteins, albumin, prealbumin, transferrin and retinol-binding protein. Serum and intraerythrocytary folic acid concentrations will be measured, as well as serum vitamin A, B1, B12, C, E, B-carotenes, Zn, Mg and Se concentrations. Moreover, the following measurements will also be obtained: red blood cell count, hematocrit, mean corpuscular volume, leukocyte count, glucose, creatinine, electrolytes, uric acid, transaminases, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl transpeptidase and bilirubin. 3. Coagulation tests: the following parameters will also be determined: platelet count, prothrombin time, and plasma fibrinogen. 4. Serum lipoproteins and others: total cholesterol, triglycerides, cHDL, cLDL, Apo A1, Apo B, lipoprotein (a) and homocysteine will be determined. 5. Diet and exercise monitoring: all participants will follow an isocaloric diet prepared according to their personal preferences. The diet will be strictly monitored during the study. Diet compliance will be assessed from 7-days diet records administered before each evaluation. This assessment will be administered by trained personnel. The foods ingested will be converted into nutritional values with the aid of the Professional Diet Balancer software (Cardinal Health Systems, Inc., Edina, MN). Physical activity will also be evaluated with the Minnesota Leisure Time Physical Activity questionnaire which has also been validated in Spain. Control of the diet and physical exercise will be carried out before and after each intervention, the same day on which the clinical examinations are performed and blood is withdrawn for immunologic studies. All variables (primary and secondary outcomes) will be measured at baseline and after each intervention period.
Completion date	01/10/2011

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	Male
Target sample size at registration	50
Key inclusion criteria	1. Males between 55 and 70 years old 2. No documented cardiovascular disease (ischaemic heart disease - angina or recent or old myocardial infarction or previous or cerebral vascular accident, peripheral vascular disease) 3. Diabetes mellitus, or three or more of the following risk factors: 3.1. Current smoking 3.2. Hypertension 3.3. Hypercholesterolaemia (low density lipoprotein [LDL]-cholesterol greater than 160 mg/dl) 3.4. High density lipoprotein (HDL)-cholesterol less than 40 mg/dl 3.5. Overweight or obese (body mass index greater than 25 kg/m^2) 3.6. Family history of premature coronary heart disease 4. Participant gives signed informed consent
Key exclusion criteria	1. Previous history of cardiovascular disease (ischaemic heart disease - angina or recent or old myocardial infarction, cerebral vascular accident, or peripheral vascular disease) 2. Any severe chronic disease 3. Alcoholism 4. Other toxic abuse
Date of first enrolment	01/10/2010
Date of final enrolment	01/10/2011

Locations

Countries of recruitment

Spain

Study participating centre

Department of Internal Medicine

Barcelona
08036
Spain

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2014		Yes	No
Results article	results	01/04/2014		Yes	No
Results article	results	01/01/2015		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes